San Diego-dependent Viking Therapeutics marked alone as a significant competitor within the weight loss drug market in February immediately after revealing promising data from a mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when provided to be a weekly injection As well as in March